Clinical trial
A Phase 1, Open-label, Randomized, Multiple-dose, Crossover Pharmacokinetic/Pharmacodynamic Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Phenotypes
NCT05162053 is registered in ClinicalTrials.gov with Jiangsu vcare pharmaceutical technology co., LTD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-label, Randomized, Multiple-dose, Crossover Pharmacokinetic/Pharmacodynamic Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Phenotypes
- Lead sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 9, 2021
- Completion date
- November 3, 2022
- Enrollment
- 128 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.